Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Trial Profile

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Dermatomyositis
  • Focus Therapeutic Use
  • Acronyms Acthar Gel

Most Recent Events

  • 10 Sep 2021 Status changed from recruiting to completed.
  • 25 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2021.
  • 21 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top